RiverVest Venture Partners’ Post

Biotech News: Wugen announces the company will initiate our pivotal Phase 2 trial for WU-CART-007 in the first quarter of 2025. This off-the-shelf, allogeneic CD7-targeted CAR-T cell therapy is designed to address the unmet needs of patients with relapsed or refractory T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL). After 20 years with limited advancements for relapsed or refractory T-ALL/LBL, we believe off-the-shelf allogeneic CD7-targeted CAR-T cell therapies may offer hope and innovation. Read today's news: https://bit.ly/40CUgSR

🌍 September is Leukemia and Lymphoma Awareness Month! 🌍 According to the National Cancer Institute (NCI), 62,770 new cases of leukemia are expected in the United States in 2024. When it comes to lymphoma, 80,620 people in the U.S. are estimated to develop non-Hodgkin lymphoma, while 8,570 new cases of Hodgkin lymphoma are also expected this year. Join PrimeVigilance in spreading awareness this month. Together, we can make a difference and work towards improving outcomes for blood cancer patients around the world. #Pharmacovigilance #leukemia #lymphoma

🌟 Will CAR-T therapies revolutionize oncology, replacing traditional cancer treatments? CAR-T therapies have shown impressive efficacy, with studies reporting complete response rates of up to 65% in patients with certain lymphomas, compared to just 32% with traditional chemotherapy. In acute lymphoblastic leukemia (ALL), CAR-T treatments have achieved remission rates of around 82% in children and young adults. In multiple myeloma, CAR-T therapies have demonstrated remission rates of up to 94%. Furthermore, CAR-T therapies typically require only a single infusion, significantly shortening the treatment duration and patient recovery time compared to the extended cycles of chemotherapy. This advancement not only improves treatment outcomes but also enhances the quality of life for patients. What are your thoughts on the future of cancer treatment? Share your insights! #Immunotherapy #CART #Oncology #MedicalInnovation #Biotechnology #Cancer #ALL #Myeloma #Lymphoma #Leukemia

Novel Therapeutics in Relapsed Setting for Diffuse Large B-Cell Lymphoma - 2024 Blood Cancer OncTalk https://lnkd.in/eDCYPJhC via @YouTube In this video, Dr. Michele Stanchina discusses novel therapeutics in the relapsed setting for Diffuse Large B-cell lymphoma (DLBCL) such as Loncastuximab, CAR T-cell therapy, and Bispecific T-cell engagers. She also discusses Cytokine Release Syndrome (CRS) and summarizes key takeaways for Diffuse Large B-cell lymphoma (DLBCL) in general. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://lnkd.in/ekmZ-Pe.

BEIGENE AND CLL SOCIETY PARTNER TO ADVANCE TEST BEFORE TREAT™ CAMPAIGN BeiGene has recently announced its new partnership with CLL Society, the world’s leading authority for chronic lymphocytic leukemia and small lymphocytic lymphoma cancer patients. Together, they are advancing Test Before Treat, an awareness campaign that aims to connect with healthcare providers and educate patients with CLL/SLL about the critical importance of biomarker testing before initial treatment and retesting at each subsequent treatment to help ensure each patient receives the most effective, personalized therapy. READ MORE... https://lnkd.in/ekkmzGzA

Lymphoma is a type of cancer caused by the uncontrolled growth of cells called lymphocytes that play a role in fighting infection. Lymphoma is the most common cancer found in people 16 to 29 years old, with over 7,000 new cases diagnosed every year in Australia. More than 30 different types of this devastating disease have been identified. Treatment may involve chemotherapy, radiation therapy, the use of stem cell transplants or immunotherapy such as CAR T-cell therapy. 15th September is World Lymphoma Awareness Day. Let us make an impact on this Day by raising its awareness. At GreenLight Clinical (#GLC), we aim to strengthen our Lymphoma #community by supporting clinical trials for the development of drugs for treating lymphoma. To find out more about GLC, please visit www.greenlightclinical.com #WLAD2024 #greenlightclinical #businessdevelopment #biotech #medtech #clinicaltrials

🚨 𝐁𝐌𝐒 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐬𝐞𝐜𝐨𝐧𝐝 𝐂𝐀𝐑-𝐓 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥! The FDA approval today marks a significant breakthrough in treating chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). ➡️ Breyanzi's second approval is based on response rate and duration of response observed in clinical trials, particularly the TRANSCEND CLL 004 study, which reported a 20% complete response rate. Breyanzi received its first approval in June 2022 for treating large B-cell lymphoma, a rapidly growing type of non-Hodgkin lymphoma. 𝐈𝐭𝐬 𝐬𝐞𝐜𝐨𝐧𝐝 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥, 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐝 𝐭𝐨𝐝𝐚𝐲, is for the treatment of CLL or SLL, both affecting lymphocytes. These CAR-T approvals broaden Bristol Myers Squibb's Breyanzi's usage to target different types of blood cancers, marking significant advancements in important treatment options for patients. Congratulations! #celltherapy #oncology #biotech #CGTweekly

Immunotherapy continues to boom in oncology, especially as new forms of adoptive cell therapy are created and tested. Three of our four stories this week are about immunotherapy, and the fourth is about using combination therapy to treat relapsed/refractory B cell lymphoma. Read more: ❇️ Cell therapy in metastatic colorectal cancer (CRC): https://buff.ly/4fBDJUp ❇️ Combination therapy in relapsed DLBCL: https://buff.ly/4dijrxx ❇️ mRNA vaccine against glioblastoma (GBM): https://buff.ly/4fLthti ❇️ First TCR therapy approved in a solid tumor: https://buff.ly/3RXujIx

Fibrin-associated LBCL (Large B-cell Lymphoma) This study presents the first case of BIA-FA-LBCL in Italy and one of the few assessed from a molecular standpoint so far.https://https://lnkd.in/ewPAQCTs #BIAALCL #BIASCC #BIALBCL #BIAFALBCL

We're counting down the days until ISPOR 2024! Join us in connecting with healthcare leaders from across the globe. If you'll be there, don't hesitate to reach out to our team - we can't wait to meet you! At ISPOR, we're excited to be presenting three abstracts. The first two are with Eli Lilly and Company using ConcertAI oncology dataset for Mantle Cell Lymphoma. They’ll be discussing the "Proportional Randomization Method to Identify Index Line of Therapy in Externally Controlled Trials" and the “Budget Impact of Pirtobrutinib for Patients With Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States.” The third is a joint abstract with Novartis using Prostate Patient360TM on a “Comparative Analysis of Different Methods of Disease Progression Data Capture in Patients With Metastatic Castration-Resistant Prostate Cancer.” Don't miss the chance to connect with us at ISPOR 2024! Schedule a meeting with our team: https://hubs.ly/Q02tvRdP0 #ISPOR2024 #HealthcareLeaders #InnovationsinHealthcare